More importantly, the chemotherapeutic drug Etoposide, which has been shown to inhibit the growth of prostate and breast cancer [59,60], reduced FOXA1 expression in our study (Figure 8A), concluding that FOXA1 may be useful as potential prognostic marker and therapeutic target. This evidence concerns the gene FOXA1 and breast cancer.